Dare Bioscience (DARE) Total Debt (2013 - 2025)

Dare Bioscience's (DARE) quarterly Total Debt came in at $10542.0 in Q3 2025, down 94.39% on a QoQ basis from $187966.0 in Q2 2025.

Dare Bioscience (DARE) Total Debt (2013 - 2025) Analysis & Trends

Dare Bioscience (DARE) has 8 years of Total Debt data on file, last reported at $10542.0 in Q3 2025.

Quarterly Total Debt changed N/A year-over-year to $10542.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $10542.0 (changed N/A YoY) and the FY2024 annual result came in at $4054.0, changed N/A from the prior year.
Total Debt fell to $10542.0 in Q3 2025, from $187966.0 in the prior quarter.
In the past five years, Total Debt ranged from a high of $1.0 million in Q1 2021 to a low of $4054.0 in Q4 2024.
A 3-year average of $382411.5 and a median of $139936.5 in 2025 frame the typical range for Total Debt.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	139.95 Bn	132.10 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.71 Bn	78.72 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	65.71 Bn	60.52 Bn	1.37 Bn	-
4	Moderna	60.45 Bn	55.31 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	42.24 Bn	37.14 Bn	1.53 Bn	1.07 Bn
6	Alnylam Pharmaceuticals	31.80 Bn	28.49 Bn	992.69 Mn	-
7	BioNTech SE	28.64 Bn	10.25 Bn	668.28 Mn	770.36 Mn
8	Insmed	27.61 Bn	26.45 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.26 Bn	26.42 Bn	-	9.34 Bn
10	Dare Bioscience	12.36 Mn	-253,077.65	-132,343.00	-

Download Data